Integra LifeSciences reports Q1 2026 revenue growth and raises full-year adjusted EPS guidance

Integra LifeSciences reported a 2.4% increase in first-quarter 2026 revenues to $391.9 million, driven by strong demand in tissue reconstruction and neurosurgery products. Adjusted earnings per share rose to $0.54 from $0.41 last year, while GAAP net loss narrowed significantly. The company reaffirmed its full-year revenue guidance of $1.662-$1.702 billion and raised adjusted EPS guidance to $2.40-$2.50, citing improved operational execution and supply reliability. New CEO Stuart Essig highlighted progress in manufacturing and product launches, with confidence in meeting full-year targets.